REGENXBIO Inc 2025年度报告

ցցANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.YesցNoտ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 duringthe preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past90 days.YesցNoտ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).YesցNoտ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.տ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control overfinancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.տ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filingreflect the correction of an error to previously issued financial statements.տ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received byany of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).տ The aggregate market value of common stock held by non-affiliates of the registrant based on the closing price of the registrant’s common stock as reported onThe Nasdaq Global Select Market on June 30, 2025, the last business day of the registrant’s most recently completed second quarter, was $385,010,782.As of February 27, 2026, there were 51,612,984 shares of the registrant’s common stock, par value $0.0001 per share, issued and outstanding. DOCUMENTS INCORPORATED BY REFERENCE Specified portions of the registrant’s definitive proxy statement with respect to the registrant’s 2026 Annual Meeting of Stockholders, which is to be filedpursuant to Regulation 14A within 120 days after the end of the registrant’s fiscal year ended December 31, 2025, are incorporated by reference into Part III of thisAnnual Report on Form 10-K. REGENXBIO INC. Form 10-K For the Year Ended December 31, 2025Table of Contents Part IInformation Regarding Forward-Looking Statements ............................................................................................... 1Industry and Market Data ..........................................................................................................................................2Item 1.Business .....................................................................................................................................................................2Item 1A.Risk Factors ...............................................................................................................................................................33Item 1B.Unresolved Staff Comments ......................................................................................................................................69Item 1C.Cybersecurity .............................................................................................................................................................69Item 2.Properties ...................................................................................................................................................................70Item 3.Legal Proceedings......................................................................................................................................................70Item 4.Mine Safety Disclosures ............................................................................................................................................70 Part IIMarket for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Item 5.Securities......